

MW MediWound

Next-Generation Enzymatic Therapeutics
For Non-Surgical Tissue Repair



Global Collaborations



EscharEx[®]

Next-Generation Enzymatic Debridement Drug Candidate for Chronic Wounds*

Rapid, effective, safe debridement for
two indications:

Venous Leg Ulcers (VLU) and Diabetic Foot Ulcers (DFU)

Easy to use topical application for all patient settings

Debrides chronic ulcers within 4-8 applications

Promotes granulation tissue and reduces bacteria & biofilm

Demonstrated superiority over SANTYL[®]

Targets a \$2.5B market

De-risked program: based on 3 successful Phase II trials

Phase III for VLU

Planned phase II/III for DFU

R&D collaborations with Mölnlycke, Solventum, MIMEDX

*Characteristics based on phase II data



Validated Enzymatic Technology Platform



Solid Balance Sheet

\$44M cash (as of Dec 31, 2024)

\$20M revenues in 2024

3:1 demand to production capacity

\$115M+ BARDA funding (to date)

\$15M+ DoD funding (to date)

€16M+ EIC funding

NexoBrid[®]

Disruptive Therapy for Burn Care FDA and EMA approved

Approved in 40+ countries; 14K+ patients treated to-date

Poised to replace standard of care for eschar removal
in severe burns

Minimizes need for surgery and significantly reduces blood loss

Topical application at bedside

Preserves viable tissue and improves patient outcomes (scar quality
and function)

c-GMP sterile manufacturing facility to support global demand

